Malondialdehyde-modified low-density lipoprotein is a useful marker to identify patients with vulnerable plaque

Circulation Journal

Volumn 76, Issue 9, 2012, Pages 2211-2217

  Tajika, Kenichiro ^a,b   Okamatsu, Kentaro ^a,b   Takano, Masamichi ^a   Inami, Shigenobu ^b   Yamamoto, Masanori ^b   Murakami, Daisuke ^b   Kobayashi, Nobuaki ^b   Ohba, Takayoshi ^b   Hata, Noritake ^b   Seino, Yoshihiko ^b   Mizuno, Kyoichi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

Author keywords

Angioscopy; Lipoprotein; Plaque vulnerability

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; MALONALDEHYDE MODIFIED LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; ANGIOSCOPY; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COLORIMETRY; COMPLEX PLAQUE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL; YELLOW PLAQUE;

AGED; ANGIOSCOPY; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC;

EID: 84865498377     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0183     Document Type: Article

References (23)

1. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983; 52: 223-261.
2. Steinberg D. Role of oxidized LDL and antioxidants in atherosclerosis. Adv Exp Med Biol 1995; 369: 39-48.
3. Steinberg D, Lewis A. Conner memorial lecture: Oxidative modification of LDL and atherogenesis. Circulation 1997; 95: 1062-1071.
4. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998; 98: 1487-1494.
5. Holvoet P, Collen D, Van de Werf F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA 1999; 281: 1718-1721.
6. Mizuno K, Miyamoto A, Satomura K, Kurita A, Arai T, Sakurada M, et al. Angioscopic coronary macromorphology in patients with acute coronary disorders. Lancet 1991; 337: 809-812.
7. Uchida Y, Nakamura F, Tomaru T, Morita T, Oshima T, Sasaki T, et al. Prediction of acute coronary syndromes by percutaneous coronary angioscopy in patients with stable angina. Am Heart J 1995; 130: 195-203.
8. Ueda Y, Ohtani T, Shimizu M, Hirayama A, Kodama K. Assessment of plaque vulnerability by angioscopic classification of plaque color. Am Heart J 2004; 148: 333-335.
9. Takano M, Jang IK, Inami S, Yamamoto M, Murakami D, Okamatsu K, et al. In vivo comparison of optical coherence tomography and angioscopy for the evaluation of coronary plaque characteristics. Am J Cardiol 2008; 101: 471-476.
10. Ishibashi F, Yokoyama S, Miyahara K, Dabreo A, Weiss ER, Iafrati M, et al. Quantitative colorimetry of atherosclerotic plaque using the L*a*b color space during angioscopy for the detection of lipid cores underneath thin fibrous cap. Int J Cardiovasc Imaging 2007; 23: 679-691.
11. Ishibashi F, Mizuno K, Kawamura A, Singh PP, Nesto RW, Waxman S. High yellow color intensity by angioscopy with quantitative colorimetry to identify high-risk features in culprit lesions of patients with acute coronary syndrome. Am J Cardiol 2007; 100: 1207-1211.
12. Inami S, Ishibashi F, Waxman S, Okamatsu K, Seimiya K, Takano M, et al. Multiple yellow plaques assessed by angioscopy with quantitative colorimetry in patients with myocardial infarction. Circ J 2008; 72: 399-403.
13. Yamamoto M, Takano M, Okamatsu K, Murakami D, Inami S, Xie Y, et al. Relationship between thin cap fibroatheroma identified by virtual histology and angioscopic yellow plaque in quantitative analysis with colorimetry. Circ J 2009; 73: 497-502.
14. Kotani K, Maekawa M, Kanno T, Kondo A, Toda N, Manabe M. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim Biophys Acta 1994; 1215: 121-125.
15. Okamatsu K, Takano M, Sakai S, Ishibashi F, Uemura R, Takano T, et al. Elevated troponin T levels and lesion characteristics in non-STelevation acute coronary syndromes. Circulation 2004; 109: 465-470.
16. Miyamoto A, Prieto AR, Friedl SE, Lin FC, Muller JE, Nesto RW, et al. Atheromatous plaque cap thickness can be determined by quantitative color analysis during angioscopy: Implications for identifying the vulnerable plaque. Clin Cardiol 2004; 27: 9-15.
17. Kobayashi N, Hata N, Kume N, Yokoyama S, Shinada T, Tomita K, et al. Matrix metalloproteinase-9 for the earliest stage acute coronary syndrome. Circ J 2011; 75: 2853-2861.
18. Tavora FR, Ripple M, Li L, Burke AP. Monocytes and neutrophils expressing myeloperoxidase occur in fibrous caps and thrombi in unstable coronary plaques. BMC Cardiovasc Disord 2009; 9: 27.
19. Loria V, Dato I, Graziani F, Biasucci LM. Myeloperoxidase: A new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediators Inflamm 2008; 2008: 135625.
20. Zhang R, Shen Z, Nauseef WM, Hazen SL. Defects in leukocytemediated initiation of lipid peroxidation in plasma as studied in myeloperoxidase-deficient subjects: Systematic identification of multiple endogenous diffusible substrates for myeloperoxidase in plasma. Blood 2002; 99: 1802-1810.
21. Takano M, Mizuno K. Coronary angioscopic evaluation for serial changes of luminal appearance after pharmacological and catheter interventions. Circ J 2010; 74: 240-245.
22. Tani S, Watanabe I, Anazawa T, Kawamata H, Tachibana E, Furukawa K, et al; Surugadai Atherosclerosis Regression Investigators. Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound. Am J Cardiol 2005; 96: 1089-1094.
23. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.